New York S09523 mandates coverage for Alzheimer's disease and related dementia treatments.

New York S09523 amends the insurance law to require coverage for medically necessary diagnostic testing and FDA-approved treatments for Alzheimer's disease and related dementias. This coverage applies to all medical, major medical, or similar comprehensive-type insurance policies, group or blanket policies, and health service corporations. The bill ensures that these treatments are not subject to step therapy requirements. The changes will take effect on January 1 following the bill's enactment.

New York S09523 mandates coverage for Alzheimer's disease and related dementia treatments.

New York S09523 amends the insurance law to require coverage for medically necessary diagnostic testing and FDA-approved treatments for Alzheimer's disease and related dementias. This coverage applies to all medical, major medical, or similar comprehensive-type insurance policies, group or blanket policies, and health service corporations. The bill ensures that these treatments are not subject to step therapy requirements. The changes will take effect on January 1 following the bill's enactment.